Stockreport

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Silence Therapeutics Plc - American Depository Share  (SLN) 
PDF Study met primary endpoint and demonstrated highly significant reductions in Lp(a) to week 36Lipoprotein(a) reduction was consistent with phase 1 resultsTopline 48-week [Read more]